Summit Therapeutics

Summit is a UK company focused on the discovery and development of novel drug candidates to treat areas of high unmet medical need. Our strategy focuses on two therapy areas: Duchenne Muscular Dystrophy, a fatal genetic muscle wasting disease and the infectious disease caused by the bacteria C. difficile.
Company Growth (employees)
Milton, GB
Size (employees)
37 (est)+61%
Summit Therapeutics was founded in 2003 and is headquartered in Milton, GB

Summit Therapeutics Office Locations

Summit Therapeutics has offices in Milton and Cambridge
Milton, GB (HQ)
Park House Park Dr 85b
Cambridge, US
1 Broadway

Summit Therapeutics Data and Metrics

Summit Therapeutics Financial Metrics

Summit Therapeutics's revenue was reported to be £1.5 m in FY, 2016 which is a 32% decrease from the previous period.

Revenue (FY, 2016)

1.5 m

Revenue growth (FY, 2015 - FY, 2016), %


Net income (FY, 2016)

(17.1 m)

Market capitalization (20-Jul-2017)

117.6 m

Closing share price (20-Jul-2017)


Cash (31-Jan-2016)

16.3 m
Summit Therapeutics's current market capitalization is £117.6 m.
GBPFY, 2014FY, 2015FY, 2016


1.8 m2.1 m1.5 m

Revenue growth, %


Pre tax profit

(6.7 m)(12.7 m)(20.1 m)

Net Income

(6.1 m)(11.4 m)(17.1 m)
GBPFY, 2014FY, 2015FY, 2016


2 m11.3 m16.3 m

Current Assets

3.1 m15.2 m20.9 m


43 k55 k83 k


4.2 m4.1 m4.1 m

Total Assets

7.3 m19.4 m25.1 m

Accounts Payable

349 k1.2 m716 k

Current Liabilities

1.9 m3.7 m3.2 m

Total Liabilities

2.5 m4.4 m3.9 m

Retained Earnings

(6.1 m)(11.4 m)(17.1 m)

Total Equity

4.8 m15 m21.1 m

Financial Leverage

1.5 x1.3 x1.2 x
GBPFY, 2014FY, 2015FY, 2016

Cash From Operating Activities

(5.9 m)(11.3 m)(17.2 m)

Cash From Financing Activities

4.5 m20.5 m22.1 m

Income Taxes Paid

607 k1.3 m3.1 m
GBPY, 2016


63.1 k

Financial Leverage

1.2 x

Summit Therapeutics Market Value History

Summit Therapeutics Online and Social Media Presence

Summit Therapeutics News and Updates

Summit Therapeutics Company Life and Culture

You may also be interested in